Anne Prener, MD, Ph.D
Administratrice indépendante
Dr. Anne Prener holds an M.D. and a Ph.D. in epidemiology from the University of Copenhagen and brings more than 25 years of experience leading clinical-stage biotechnology companies through critical development and value-creation milestones. She has served as Chief Executive Officer of multiple companies, including Freeline Therapeutics, a liver-directed gene therapy company she scaled from preclinical stage to a fully integrated organization with two clinical programs and commercial-scale manufacturing, and Gyroscope Therapeutics. Earlier in her career, Dr. Prener held senior leadership roles at Baxalta and Novo Nordisk, where she was instrumental in building late-stage hematology portfolios and securing multiple product approvals in the US and EU. She has been instrumental in bringing six biologics through development, approval, and launch.